Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
44.94 USD | +0.45% | +2.16% | -12.41% |
May. 10 | Bristol-Myers Squibb Says Phase 3 Trial of Opdivo in Lung Cancer Fails to Meet Primary Endpoint | MT |
May. 10 | Bristol Myers Squibb Cancer-Treatment Trial Misses Endpoint | DJ |
Financials (USD)
Sales 2024 * | 46.02B | Sales 2025 * | 46.16B | Capitalization | 91.1B |
---|---|---|---|---|---|
Net income 2024 * | -5.4B | Net income 2025 * | 10.22B | EV / Sales 2024 * | 2.83 x |
Net Debt 2024 * | 39.2B | Net Debt 2025 * | 31.85B | EV / Sales 2025 * | 2.66 x |
P/E ratio 2024 * |
-17.1
x | P/E ratio 2025 * |
8.49
x | Employees | 34,100 |
Yield 2024 * |
5.35% | Yield 2025 * |
5.62% | Free-Float | 69.28% |
Latest transcript on Bristol-Myers Squibb Company
1 day | +0.45% | ||
1 week | +2.16% | ||
Current month | +2.28% | ||
1 month | -10.64% | ||
3 months | -9.78% | ||
6 months | -11.20% | ||
Current year | -12.41% |
Managers | Title | Age | Since |
---|---|---|---|
Chief Executive Officer | 53 | 15-01-31 | |
David Elkins
DFI | Director of Finance/CFO | 55 | 19-11-19 |
Greg Meyers
CTO | Chief Tech/Sci/R&D Officer | - | - |
Members of the board | Title | Age | Since |
---|---|---|---|
Phyllis Yale
BRD | Director/Board Member | 66 | 19-11-19 |
Peter Arduini
BRD | Director/Board Member | 59 | 16-03-31 |
Derica Rice
BRD | Director/Board Member | 59 | 20-08-31 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
12.97% | 0 M€ | +12.39% | - | |
4.99% | 2 M€ | -.--% | ||
4.01% | 0 M€ | +7.69% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-05-10 | 44.94 | +0.45% | 8,699,595 |
24-05-09 | 44.74 | +2.45% | 10,776,314 |
24-05-08 | 43.67 | -0.84% | 11,928,339 |
24-05-07 | 44.04 | +0.32% | 11,026,912 |
24-05-06 | 43.9 | -0.20% | 9,127,651 |
Delayed Quote Nyse, May 10, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-12.41% | 91.1B | |
+30.38% | 684B | |
+26.51% | 568B | |
-4.36% | 361B | |
+19.30% | 329B | |
+3.73% | 284B | |
+16.70% | 240B | |
+8.78% | 208B | |
-7.93% | 200B | |
+7.68% | 166B |
- Stock Market
- Equities
- BMY Stock